CRANBURY, N.J., May 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 12/952,238 (the '238 application). The application includes composition of matter claims on a new class of melanocortin receptor- specific peptides for sexual dysfunction and other indications.
The '238 application is the first patent application to issue covering a novel family of melanocortin-4 receptor agonist peptides. The melanocortin-4 receptor mediates sexual response, and agonists have been studied for treatment of both erectile dysfunction and female sexual dysfunction. Palatin's bremelanotide product, a melanocortin-4 receptor agonist peptide drug administered using an autoinjector, has recently completed Phase 2 human studies for female sexual dysfunction, with pivotal Phase 3 clinical studies scheduled to start later this year.
The peptides in the '238 application demonstrated effects on sexual function in animal models. Palatin is evaluating these peptides as potential follow-on or second generation products for treatment of sexual dysfunction. The melanocortin-4 receptor also has potential utility in treatment of obesity, metabolic syndrome and other indications.
"As we move into Phase 3 with bremelanotide for female sexual dysfunction, we are pleased to have new peptides with improved profiles suitable for use as second generation products," stated Carl Spana , Ph.D., President and CEO of Palatin.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued
|SOURCE Palatin Technologies, Inc.|
Copyright©2012 PR Newswire.
All rights reserved